Startups
Mironid
Develops small molecule medicines for hereditary kidney disease. Its LoAc drug candidates target abnormally high cAMP levels that drive fluid-filled cyst growth in autosomal dominant polycystic kidney disease.
Team
Adele RowleyChief Scientific Officer |
Allister WilliamsHead of Programme Management |
 Anja HarmeierBoard Member |
Daniela CoutoInvestor Director |
David HendersonHead of Biology |
Elaine V. JonesChairman |
Elizabeth RoperInvestor Director |
Julia AdamHead of Medicinal Chemistry |
Maina BhamanInvestor Director |
Michael MooreNon-Executive Director |
Neil WilkieChief Executive Officer |
Richard BrooksHead of Finance |